Detailed narrative
FY26 Performance Overview
Champions Oncology achieved record annual revenue and positive adjusted EBITDA for fiscal 2026, marking the first time since fiscal 2022 that the company reported positive adjusted EBITDA in all four quarters. This performance was driven by the strong execution of its core translational oncology services business, which saw significant growth and operational leverage. The company also continued its strategic investments in its data platform and therapeutic subsidiary, Corellia, which contributed to a GAAP net loss despite the adjusted EBITDA profitability.
Translational Oncology Services (TOS) Business Strength
The core services business delivered its strongest year in company history, with revenue reaching $58.7 million, an increase of approximately 12% year-over-year. This growth was attributed to successful study conversions and the differentiation provided by the PDx Bank. Management highlighted the operating leverage achieved, as this growth was delivered without material headcount additions, indicating improved efficiency. The company expects services growth to moderate to a more normalized pace in the near term after this strong conversion.
Data Business Evolution and Strategic Importance
The data business experienced a year-over-year revenue decline to $800,000 in FY26 from $4.7 million in FY25, primarily due to a large, non-recurring📎 transaction in the prior year. However, the company emphasized strategic progress, including expanding its customer base through smaller licensing agreements and growing its pipeline of larger opportunities. The integration of deeply characterized models with machine learning and AI is seen as a key long-term differentiator for drug discovery, despite expected revenue fluctuations in the near term.
Corellia Therapeutic Subsidiary Development
Corellia, the wholly owned therapeutic subsidiary, continues to generate compelling data, reinforcing confidence in its scientific and commercial potential. The company is actively engaged in discussions with venture capital groups and pharmaceutical partners to secure external funding or licensing partnerships. While the biotech funding environment presents challenges, management's FY27 budget assumes Corellia will be fully funded, with potential for investment redeployment if external capital is secured.
Operational Efficiency and Margin Improvement
A key operational initiative in FY26 was bringing radiopharmaceutical activities in-house, which began to positively impact financial results. This transition led to a significant improvement in fourth-quarter gross margin to 51% from 41% in the prior year quarter, and a full-year gross margin increase to 48% from 46%. The company expects continued benefits from this initiative, leading to further margin expansion over time⏳ as outsourced costs decline.
Financial Discipline and Balance Sheet Health
Champions Oncology maintained financial discipline throughout FY26, ending the year with $4.9 million in cash and no debt. This healthy balance sheet provides the financial flexibility to continue executing its strategy and investing in growth initiatives. The company remains committed to improving profitability and maintaining financial discipline in fiscal 2027, evaluating opportunities to invest where they can generate attractive long-term returns.